1 Title

2 3	High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of <i>Plasmodium vivax</i> malaria in Indonesia and Papua New Guinea: The
4	SCOPE implementation study protocol
5	
6	Authors
7	Jeanne Rini Poespoprodjo, MD, PhD ^{1,2}
, 8	Moses Laman, MD, PhD^3
9	Ayodhia Pitaloka Pasaribu, MD, PhD ^{4,5}
10	Inge Sutanto, MD, PhD ⁶
	Erni Nelwan, MD, PhD ⁶
11	
12	Liony Fransisca, MD ²
13	Enny Kenangalem, MD ²
14	Faustina Helena Burdam, MD ²
15	Vincent Jimanto, MD ⁵
16	Framita Ainur, MD ⁵
17	Azkarunia Pasidiaz Hutagalung, MD ⁵
18	Sherley Angeline, MD ⁷
19	Adela Putri, MD ⁷
20	Ari Winasti Satyagraha, Dr.sc.hum ⁸
21	Minerva Theodora, MD ⁹
22	William Pomat, PhD ³
23	Maria Ome-Kaius, MD, PhD ³
24	Mary Malai, MD ³
25	Cynthia Abegini, BRH ³
26	Irene Pukai, BRH ³
27	Sharol Ronkentuo, BRH ³
28	Yolyne Amdara, BRH ³
29	Leo Makita, MPH ¹⁰
30	Evelien Rosens, MSc ¹¹
31	Paul Daly, MPH ¹¹

32 Rachael Farquhar, MPH¹¹

- 33 Nicholas M. Douglas, FRACP ^{12,13,14}
- 34 Kylie Mannion, Grad Dip,¹²
- 35 Ella Curry, MD, MPH¹²
- 36 Annisa Rahmalia, MD, MPH, PhD¹²
- 37 Vanessa S Sakalidis, PhD¹²
- 38 Jacklyn Adella, MD¹²
- 39 Grant Lee, BSc¹²
- 40 Benedikt Ley, PhD¹²
- 41 Angela Devine, PhD^{12, 16}
- 42 Patrick Abraham, MPH^{12,16}
- 43 Julie A. Simpson, PhD^{15,19}
- 44 Katelyn Brown, M(Biost)^{12, 15}
- 45 Thy Do, PhD¹⁷
- 46 Heike Huegel, MSc ¹⁷
- 47 Helen Demarest, PhD¹⁷
- 48 Elodie Jambert, PharmD, MPH¹⁷
- 49 Tanyaporn Wansom, PhD, MD¹⁷
- 50 Stephan Duparc, PhD, MD¹⁷
- 51 Leanne J. Robinson, PhD^{2,11,18}
- 52 Ric N. Price, FRCP^{12,19,20}
- 53

54 Affiliations

- ¹ Centre for Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada,
 Yogyakarta, Indonesia Indonesia
- 57 ² Yayasan Pengembangan Kesehatan dan Masyarakat Papua, Timika, Papua, Indonesia
- ³ Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
- ⁴ Department of Pediatrics, Medical Faculty, Universitas Sumatera Utara, Medan, Indonesia
- ⁵ Tridarma Healthcare Empowerment Foundation, Medan, Sumatera Utara, Indonesia
- ⁶ Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
- 62 ⁷ Hanura Puskesmas, Lampung, Indonesia
- 63 ⁸ National Research and Innovation Agency (BRIN), Jakarta, Indonesia
- ⁹ Indonesian National Malaria Control Program, Jakarta, Indonesia
- 65 ¹⁰ National Malaria Control Program, National Department of Health, PNG

- 66 ¹¹ Burnet Institute, Melbourne, VIC Australia
- 67 ¹² Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin
- 68 University, Darwin, NT, Australia
- ¹³ Department of Infectious Diseases, Christchurch Hospital, Te Whatu Ora Waitaha, Christchurch,
 New Zealand
- 71 ¹⁴ Department of Medicine, University of Otago, Christchurch, New Zealand
- ¹⁵ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The
 University of Melbourne, Melbourne, Australia
- ¹⁶ Centre for Health Policy, Melbourne School of Population and Global Health, The University of
 Melbourne, Melbourne, Australia
- 76 ¹⁷ Medicines for Malaria Venture, Geneva, Switzerland
- ¹⁸ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC,
 Australia
- ¹⁹ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
 Oxford, Oxford, UK
- ²⁰ Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University,
 Bangkok, Thailand
- 83
- 84 **Corresponding author**:
- 85 Vanessa Sakalidis, PhD
- 86 Email: scopestudygroup@gmail.com
- 87 Address: Global and Tropical Health Division, Menzies School of Health Research, PO Box 41096,
- 88 Casuarina, Darwin, NT 0811, Australia
- 89
- 90 Word count: 5275
- 91 Keywords
- 92 Plasmodium vivax, Malaria, Primaquine, G6PD, Haemolysis, Indonesia, Papua New Guinea
- 93
- 94

95 Abstract

96	Introduction: <i>Plasmodium vivax</i> malaria remains an important threat to the public in the Asia Pacific
97	region. Preventing <i>P. vivax</i> relapses is crucial for reducing morbidity from malaria and ultimately
98	controlling and eliminating this species. Primaquine is the only widely available drug with antirelapse
99	activity against dormant stages of <i>P. vivax</i> . Its widespread use in clinical practice is limited by its
100	potential to cause severe haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD)
101	deficiency.

102 Methods and analysis: The primary aims of this staged, binational, multicentre, before-and-after 103 implementation study are to determine the safety, feasibility, and cost-effectiveness of a revised 104 package of case management interventions for improved *P. vivax* radical cure. The interventions 105 include: i) pre-treatment testing of patients for G6PD deficiency using a semi-guantitative point-of-106 care device from SDBiosensor (ROK); ii) prescription of high dose primaquine (7mg/kg total dose) 107 either over 7 days for G6PD normal patients (≥70% activity) or 14 days for intermediate patients (30-108 <70% activity), or lower dose weekly primaquine over 8 weeks for deficient patients (<30% activity); 109 iii) improved patient education processes; iv) routine community-based review on day 3 (and day 7 110 for Stage 1) and v) enhanced malariometric surveillance and community pharmacovigilance. Stage 1 111 of the study (800 patients) will be implemented at 4 community clinics across Indonesia and Papua 112 New Guinea (PNG) and will focus on analysis of treatment safety. If safety of the intervention is 113 confirmed during Stage 1, the study will proceed to Stage 2, in which patient recruitment will be 114 expanded to 10 clinics across Indonesia and PNG, and the feasibility of the similar intervention 115 package will be assessed, but with a single community-based review on day 3. Stage 2 will run for 12 116 months and recruit approximately 11,410 patients. Mixed methods analyses of Stage 2 data will 117 focus on the operational feasibility and cost-effectiveness of the revised case management package, 118 with effectiveness determined through analysis of individual-level risk of P. vivax recurrence and 119 population-level changes in incidence (with comparison to the pre-implementation period).

120 Feasibility will be assessed via qualitative observations, in-depth interviews and focus groups of

121 health care workers and participants.

Discussion: The intervention package will provide critical information on the safety, feasibility and cost-effectiveness of achieving radical cure with G6PD testing prior to high dose primaquine treatment and community-based follow-up. The study results will inform national malaria programs aiming to eliminate *P. vivax* in Indonesia and PNG by 2030.

126 Ethics and dissemination: This study has been approved by the World Health Organization Ethics

127 Committee (Indonesia: ERC 0003810, PNG: ERC 0003892); Menzies School of Health Research (HREC:

128 2023-4524), Alfred Health (Burnet Institute) (Project No: 18/23), University of Gadjah Mada

129 (KE/FK/0079/EC/2023), University of Indonesia (KET-347/UN2.F1/ETIK/PPM.00.02/2023), University

130 of Sumatra Utara (80/KEPK/USU/2023), Institute of Tropical Medicine (1655/23), PNG Institute of

131 Medical Research (PNGIMR) (IRB: 22.02), and the PNG National Department of Health Medical

132 Research Advisory Committee (MRAC: 22.66). The study was registered on clinicaltrials.gov for

- 133 Indonesia: NCT05879224 and PNG: NCT05874271. All participants will provide written, informed
- 134 consent to join the study. For qualitative observations of health workers, a waiver of consent was

135 granted by all ethics committees, and health centres will be made aware that observations on staff

136 will be carried out. Dissemination plans include presentations at scientific conferences, peer-

137 reviewed publications, and reporting at the national and community level.

138

139 Strengths and limitations of this Study

The staged design of this study will enable confirmation of the safety of high daily dose
 primaquine and provide operational insights on G6PD testing and community-based reviews,
 thereby facilitating the adoption of optimal practices in preparation for wide scale roll-out.

- Stage 2 will follow real-world conditions with treatment and follow-up embedded within
 local clinic procedures and implemented by clinic healthcare staff and community-based
 health workers. These efforts will enable a realistic assessment of the interventions'
 feasibility, cost-effectiveness, and scalability.
- Study sites in Indonesia and PNG are publicly funded facilities servicing populations from areas with markedly different malaria endemicity and workloads, supporting the generalisability of our results to regions across both countries with varying malaria epidemiology.
- Implementation of the intervention may be limited by the informed consent process,
 potentially restricting enrolment and coverage of the intervention across the study clinics.
- Multiple time-varying confounders, such as government-initiated malaria control activities,
 may influence malaria incidence and, therefore, impair the ability to determine the true
 population-level impact of the study interventions.

157 BACKGROUND

158 Plasmodium vivax has become the predominant cause of malaria in the Asia-Pacific region (1). P. 159 vivax is more difficult to eliminate than P. falciparum because it forms dormant liver stages 160 (hypnozoites) that can reactivate weeks to months after the initial infection, resulting in recurrent 161 blood stage infections, known as relapses. In some endemic regions, approximately 80% of P. vivax 162 cases are caused by relapses (2). In 2022, a total of 101,300 cases of vivax malaria were reported in 163 Indonesia and 211,000 cases in Papua New Guinea (PNG), with the most significant burden occurring 164 in remote and rural areas (3). The governments of both countries have committed to eliminating P. 165 vivax by 2030; accomplishing this ambitious goal will require innovative strategies to ensure the 166 widespread availability of well-tolerated and effective radical cure of individuals harbouring blood 167 and/or liver stages of the parasite.

168 The 8-aminoquinoline compounds, primaguine and tafenoquine, are the only licensed antimalarial 169 drugs that kill hypnozoites and thus can prevent subsequent relapses of P. vivax. Both drugs can 170 cause severe haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (4, 171 5). Tafenoquine was approved by the US and Australian health authorities in 2018 and is given as a 172 single dose, facilitating patient adherence (6-8). Currently, tafenoquine can only be prescribed in 173 combination with chloroquine to patients with >70% G6PD enzymatic activity, making access to this 174 drug limited in the many endemic countries where routine G6PD testing is unavailable (9). 175 Primaguine has been the primary treatment for preventing *P. vivax* relapses for almost 70 years and 176 is used in combination with chloroquine and artemisinin-based combination therapies (ACTs) (5). 177 Primaguine is widely available, but its population-level effectiveness is confounded by suboptimal 178 dosing, poor adherence of patients to prolonged treatment courses (10) and the reluctance of 179 healthcare providers to prescribe the drug due to concerns of severe haemolysis in G6PD-deficient 180 patients (11).

181

182 The World Health Organization (WHO) antimalarial treatment guidelines currently recommend a low-183 dose primaguine regimen (total dose of 3.5mg/kg administered as 0.25mg/kg/day over 14 days or 184 0.5 mg/kg/day over 7 days) (12). The 14-day regimen is most commonly used in P. vivax-endemic 185 countries (13). It is recommended that all patients are tested for G6PD deficiency before 186 administration of primaquine. If an individual is diagnosed with G6PD deficiency (<30% enzyme 187 activity), then an 8-week regimen of 0.75mg/kg primaquine administered once per week is 188 recommended (12). In PNG, the national policy for radical cure is primaguine after pre-treatment testing for G6PD deficiency, combined with blood schizonticidal treatment with artemether-189 190 lumefantrine (14). The same radical cure regimen in Indonesia is combined with dihydroartemisinin-191 piperaquine (15). In practice, G6PD testing is rarely available and hence the national malaria control 192 programmes (NMCPs) recommend a low daily dose of primaguine (0.25 mg/kg/day) administered 193 over 14 days to reduce the risk of drug-induced haemolysis (11, 13). Adherence to this prolonged 194 treatment course is typically poor when unsupervised (16, 17). Partial supervision, conversely, has 195 been shown to improve adherence and anti-relapse effectiveness (10, 18, 19).

196

197 The antirelapse efficacy of primaguine is related to the total dose administered, whereas safety and 198 tolerability are related to the daily dose administered (20). A recent meta-analysis of the antirelapse 199 efficacy of primaquine demonstrated that the overall risk of recurrent P. vivax within 6 months was 200 51.0% (95% confidence interval (CI) 48.2–53.9%) in patients who were not treated with primaquine, 201 19.3% (95%CI: 15.9-21.9%) in patients treated with low-dose primaguine (~3.5mg/kg total dose), and 202 8.1% (95% CI: 7.0-9.4%) for patients treated with high-dose primaquine (~7mg/kg total dose). The 203 benefits of the higher total dose regimen were apparent in both low and high relapse periodicity 204 areas (21).

206 Reducing the duration of primaguine treatment has the potential to improve adherence, but requires 207 the same total dose to be administered over a shorter period, thereby increasing the daily dose 208 needed and the subsequent risk of drug induced haemolysis for patients. Two recent clinical trials 209 conducted in Thailand, Afghanistan, Indonesia, Ethiopia and Vietnam (22, 23) have demonstrated 210 that a short-course high daily dose of primaquine (1mg/kg/day over 7 days – PQ7) is non-inferior to 211 the standard high dose regimen (0.5 mg/kg/day administered over 14 days with supervision – PQ14). 212 However, PQ7 was associated with more adverse events, particularly gastrointestinal intolerability 213 (22, 23). The latter can be mitigated by coadministration with food.

214 G6PD deficiency is an X-linked inherited trait. Whereas males are hemizygous normal or deficient, 215 females can be homozygous normal, homozygous deficient or heterozygous for the G6PD gene (24). 216 The latter is associated with a variable degree of intermediate deficiency and an increased risk of 217 haemolysis (25, 26). A recent systematic review demonstrated that early indicators of significant 218 haemolysis are typically apparent within 5 days of treatment commencement and usually preceed 219 severe clinical compromise and the need for medical intervention (27). These findings suggest that 220 routine clinical review within 3-5 days of starting primaguine may facilitate early detection of 221 haemolysis so that treatment can be ceased and severe consequences of primaquine-induced 222 haemolysis avoided (27).

223

Over the last decade a series of point-of-care tests for G6PD deficiency have been developed and marketed to screen for patients at risk of primaquine or tafenoquine-induced haemolysis (28-30). The SD Biosensor provides reliable differentiation of patients with deficient (<30%), intermediate (30-<70%) and normal (≥70%) G6PD activity within 2 minutes using one drop of capillary blood, therefore lending itself to pre-treatment testing.

229

230 In collaboration with Indonesian and PNG policymakers, the SCOPE study was devised to evaluate a

231 revised and enhanced P. vivax case management protocol developed to improve access to well-

232 tolerated and effective radical cure. The study is anticipated to inform Indonesian and PNG treatment

233 guidelines and is relevant to other *P. vivax* endemic countries.

234

235 METHODS AND ANALYSIS

236 Introduction to Study Design and Setting

- 237 The SCOPE study is a pragmatic, staged, binational, multicentre, before-versus-after implementation
- study of a revised case management package aimed at optimising radical cure for patients with vivax
- 239 malaria presenting to community health clinics in Indonesia and PNG (Figure 1). Ten publicly funded
- clinics (6 in Indonesia and 4 in PNG) servicing areas with widely disparate *P. vivax* incidence have
- been selected for the study (Figure 2). The annual caseloads range from 412 to 4,937 patients per
- annum and this spectrum of endemicity will support the generalisability of study results (Table 1).

243 The revised case management protocol incorporates five novel components:

- 244 i. Pre-treatment testing of patients for G6PD deficiency using the semi-quantitative point-of 245 care SD Biosensor device.
- 246 ii. Prescription of high dose primaquine (7mg/kg total dose) over 7 days (G6PD normal patients

247 - ≥70% activity, ≥6.1 U/gHb), or over 14 days (intermediate patients – 30-<70% activity, 4.1-

- 248 6.0 U/gHb) or primaquine one a week for 8 weeks (deficient patients <30% activity, ≤4.0
 249 U/gHb) (Table 2).
- 250 iii. Improved patient education processes, including supervision of the first dose of primaquine
 251 and counselling regarding key risks and benefits of therapy as well as the necessity to take
 252 doses with food.

- iv. Routine community-based review on day 3 (and day 7 for Stage 1) for the dual purpose of
- 254 encouraging adherence to primaquine and detecting early warning signs of impending
- 255 severe haemolysis and other adverse effects
- 256 v. Enhanced malariometric surveillance and community pharmacovigilance to support wider-
- 257 scale use of the revised case management package

258

- 259 The study uses a staged approach. Stage 1 aims to build confidence that short course, high dose
- 260 primaquine can be implemented safely before progressing to Stage 2, in which a large-scale
- 261 implementation study will be conducted of the revised case management protocol under conditions
- 262 more closely matching real-world practice. The overarching aim of the study is to determine the
- safety, operational feasibility and cost-effectiveness of the revised case management protocol. The
- study will be conducted over 21 months, and the results will be reported in line with the CONSORT
- 265 extension (31) and SPIRIT statement (32) (Supplementary data 1).

267

268 Figure 1. Study schedule

269

- 270 Figure 2. Location of study clinics
- 271
- 272
- 273 Table 1: Study Clinics estimated P. vivax episodes per year.

Clinic name	Country	Locality	Estimated total number of <i>P. vivax</i> episodes per year	Estimated maximum recruitment in SCOPE Stage 2 (95%)
Timika Indonesia Timika, Central Papua		Timika, Central Papua	3,173	3,014
Bhintuka	Indonesia	Timika, Central Papua	1,164	1,106
Pasar Sentral Indonesia Timika, Central Papua Papua		4,937	4,690	
Wania Indonesia Timika, Central Papua Papua		3,681	3,497	
Tanjung Leidong			500	475
Hanura	Indonesia	Lampung	450	428
Baro	PNG West Sepik		417	396
Mugil	PNG	Madang	1,044	992
Napapar	PNG	East New Britain	412	391
Wirui	PNG	East Sepik	1,382	1,313
		Total	17,160	16,302

Footnotes: Estimates based on previous clinic records and number of patients with P. vivax recruited over last 12 months.

274 275 276 Maximum enrolment assumes 5% of patients are ineligible because they are pregnant, lactating or under 6-12 months of age.

	Pre Implementation ¹	Stage 1 Safety & Feasibility	Stage 2 Implementation
G6PD Activity >70% (≥6.1 U/gHb)		ACT plus high-dose PQ7 (1mg/kg/day)	ACT plus high-dose PQ7 (1mg/kg/day)
G6PD Activity 30- 70% (4.1-6.0 U/gHb)	ACT plus low dose PQ14 (0.25 mg/kg/day)	ACT plus high-dose PQ14 (0.5 mg/kg/day)	ACT plus high-dose PQ14 (0.5 mg/kg/day)
G6PD Activity <30% (≤4.0 U/gHb)		ACT plus PQ8W (0.75 mg/kg/week)	ACT plus PQ8W (0.75 mg/kg/week)
Pregnant ²			
Lactating	Treatment as per	Ineligible for study, treatment as per national guidelines	Ineligible for study, treatment as per national guidelines
<6m or <5kg in Indonesia <1 year in PNG			
Hb <8g/dL	national guidelines		
Previous adverse reaction to PQ			
Severe malaria			

Table 2. Summary of *P. vivax* patient eligibility and treatment in the different stages of the study

G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin; ACT: Artemisinin-based combination therapies ; PQ: Primaquine.

¹ No G6PD testing – data during this stage will be gathered from ongoing surveillance.

² Confirmed pregnancy or pregnancy status unknown.

196 Study components and data collection

197 Pre-implementation

198 The study will commence with a pre-implementation stage during which continuous malariometric 199 surveillance at all 10 clinics will document clinic case numbers, building upon pre-existing 200 surveillance data collection systems. Incidence data collected during the pre-implementation and 201 Stage 1 recruitment periods (Figure 1) will provide a reference for comparing post-implementation 202 incidence. Midway through the pre-implementation stage, 200 consecutive patients with fever 203 presenting to each clinic will be recruited into a cross-sectional survey assessing the microscopy-204 based prevalence of P. vivax and G6PD activity (Table 3, Figure 3). The pre-implementation phase 205 will last three months for the four clinics participating in Stage 1 of the study and 9 months for the 206 remaining 6 clinics.

207

Research Activity	Day of Collection	Study Procedures	Data Collection	
Surveillance	Day 0	Routine care only	Routine clinic data	
Pre-implementation Survey	Day 0	 Written informed consent Capillary blood sample for malaria diagnosis, G6PD and Hb 	 Malaria diagnosis, Hb and G6PD activity 	
Community Continuous Pharmacovigilance		 Passive detection of serious adverse events in patients presenting to clinic and hospital 	 Records of all serious adverse events (Supplementary Material 4) 	
Qualitative Interviews and Focus Groups	Continuous	 Field testing In-depth interviews and focus group tools with key stakeholders Observations of routine health care activities 	 Transcripts and summaries of interviews Observations notes and memos 	
Health Economic Survey	Day 0 and Day 7	 Household cost survey per P. vivax episode at each clinic 	 Direct and indirect costs to patients and any caregivers 	

208 Table 3. Study Procedure and Data Collection in Pre-implementation Stage

²⁰⁹ G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin.

211 Stage 1

212	Following three months of pre-implementation, Stage 1 of the SCOPE study will commence at two
213	clinics in Papua, Indonesia and two in PNG, with a planned recruitment duration of 6-12 months.
214	This study component aims to provide preliminary safety and feasibility data before progressing to
215	Stage 2 at all ten clinics. A total of 800 patients with non-severe P. vivax mono- or mixed species
216	infection diagnosed by microscopy or rapid diagnostic test will be enrolled (500 in Indonesia and 300
217	in PNG) and, following pre-treatment G6PD activity assessment using the SD Biosensor, patients will
218	receive primaquine according to the dosing schedules outlined above (Table 2 and Supplementary
219	Data 2). Community-based follow-up assessments by study nurses will be conducted on day 3 and
220	day 7 of treatment (Supplementary Data 3; Level 2 Review Form), with G6PD activity and
221	haemoglobin assessed on both days. Patients with severe adverse events (SAE) or adverse events of
222	special interest (AESI) will be referred to the clinic for a health practitioner-led clinical review
223	(Supplementary Data 3; Level 3 Review Form and SAE form) and referred to the hospital for medical
224	management if appropriate. All patients will also receive enhanced education and counselling as per
225	the study interventions specified previously (Table 4).
220	Figure 2. Calculus of equalment interventions and eccessions at
226 227	Figure 3. Schedule of enrolment, interventions, and assessments.
228 229 230 231 232 233	¹ Day 3 review may be a phone call if the CHW cannot access the patient at home, or at the clinic if the patient presents there. ² During Stage 2 200 consecutive febrile patients at each clinic will be consented for the post-implementation survey, which includes the following procedures: Hb, G6PD and Microscopy only. If positive for vivax malaria, patients will also be recruited to Stage 2. ³ Microscopy will only be performed for 200 consecutive febrile patients at each clinic during post-implementation survey. not Stage 2.

- ²³³ Implementation survey, not stage 2.
 ⁴Any AESI/SAE identified during study participants' primaquine treatment will be captured.

245 Table 4 Study Procedure and Data Collection in Stage 1

Research Activity	Day of Collection	Study Procedures	Data Collection
Enrolment and Baseline	Day 0	 Clinical review Capillary blood sample for malaria diagnosis by microscopy or rapid diagnostic test (clinic procedure) Written informed consent If malaria positive, a 2nd capillary blood sample for G6PD and Hb measurement Treatment prescribed Education package Supervision of first dose Supply of drugs 	 Routine clinic data Day 0 Hb and G6PD activity, malaria diagnosis, PQ treatment
Level 2 Review	Day 3 and 7	 Capillary blood sample for Hb measurement Signs and symptoms questionnaire by research nurse 	 Day 3 signs and symptoms Day 7 signs and symptoms Day 3 Hb Day 7 Hb SAEs and AESIs
Level 3 Review	When referred from Level 2	 Capillary blood sample Hb measurement Signs and symptoms questionnaire by medical practitioner 	 Hb, MetHb Signs and symptoms SAEs and AESIs
SAE Form	Hospitalisation or death	 Capillary blood sample Hb measurement Other laboratory tests Clinical management Classification of SAE 	 Hb, other laboratory tests Clinical management SAE classification
Community Pharmacovigilance	Continuous	 Passive detection of SAEs and AESIs 	All SAEs and AESIs
Qualitative Continuous		 IDI, focus groups with patients, key stakeholders and community members of acceptability of revised case management strategy 	 Transcripts and summaries of interviews Observations notes and memos

G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin; MetHb: Methaemoglobin SAE: serious adverse event; AESI: adverse event of special interest; IDI: in-depth interview.

250

251 Stage 2

252	The Stage 2 implementation study will run for 12 months and will recruit all eligible patients with P.
253	vivax mono- or mixed species infection presenting to one of 10 study clinics across Indonesia and
254	PNG. Conditions during this stage are designed to emulate real-world practice as closely as possible.
255	Stage 2 will follow the same study procedures as Stage 1, except that clinic (rather than research)
256	staff will perform consent procedures and G6PD testing, and follow-up will be reduced to a single
257	clinical review (either in person or by phone) on day 3 (Supplementary Data 3; Level 1 Review Form).
258	The latter will be conducted by a Community-Based Health Worker (CbHW) or village midwife rather
259	than a research nurse. Patients with symptoms or signs of AESIs or SAEs will be referred to the clinic
260	for a Level 2 or Level 3 clinical review (Supplementary data 3; Level 2 and Level 3 Review Form). The
261	subsequent review and management of the patient will be the same as in Stage 1, with referral to
262	the site medical practitioner as necessary. In Stage 2, patients re-presenting with vivax malaria will
263	be eligible for repeat enrolment (Table 5).

264

Table 5 Procedure and Clinical Data Collection in Stage 2.

tudy Procedures	Data Collection
Clinical review	 Routine clinic data
Capillary blood for malaria diagnosis by microscopy or rapid diagnostic test (clinic procedure) Written informed consent If malaria positive, a 2 nd capillary sample for G6PD and Hb measurement Treatment prescribed Education package Supervision of first	• Day 0 Hb and G6PD activity
	Clinical review Capillary blood for malaria diagnosis by microscopy or rapid diagnostic test (clinic procedure) Written informed consent If malaria positive, a 2 nd capillary sample for G6PD and Hb measurement Treatment prescribed Education package

		•	
Level 1 Review	Day 3	 Symptom questionnaire by CbHW 	 Patient follow-up Symptoms and signs of patients referred to clinic SAEs and AESIs
Level 2 Review When referred from Level 1 review or patient presenting to health facility		 Capillary blood sample for Hb measurement Signs and symptoms questionnaire by clinic nurse 	 Day 3 signs and symptoms Day 3 Hb SAEs and AESIs
Level 3 Review	When referred from Level 2	 Capillary blood sample Hb measurement Signs and symptoms questionnaire by medical practitioner 	 Hb, Met Hb Signs and symptoms SAEs and AESIs
Community Pharmacovigilance	Continuous	 Passive detection of SAEs and AESIs 	 All SAEs and AESIs
Qualitative Interviews, focus group discussions (FGDs), Photovoice and observations	Continuous	 IDI, focus groups with key stakeholders and community members of acceptability of revised case management strategy Photovoice (PNG only) with community members of revised case management strategy 	 Transcripts and summaries of interviews and FGDs Observations notes and memos Photos, summaries of transcripts from photovoice FGDs.
Health Economic Survey	Day 0 and Day 7 for household costs Continuous for provider costs	 Household cost survey per <i>P. vivax</i> episode at each clinic Ingredients-based provider costs at selected clinics 	 Direct and indirect costs to patients and any caregivers Provider costs for each component of the revised case management strategy
Post-implementation Survey	6 months into Stage 2	 Written informed consent Capillary blood sample for malaria diagnosis, G6PD and Hb 	 Malaria diagnosis, Hb and G6PD activity

266
 266 G6PD: Glucose-6-phosphate dehydrogenase; Hb: haemoglobin; MetHb: Methaemoglobin; SAE: serious adverse event; AESI:
 267 adverse event of special interest; IDI: in-depth interview; CbHW: community-based health worker.

271 Health Economics

272 Detailed cost questionnaires will be completed by 30 consecutive patients (or their guardians) 273 presenting with *P. vivax* malaria at each clinic (total of 300 patients) to determine the direct and 274 indirect costs to households. In Indonesia, this will be completed during the pre-implementation 275 stage and the final 6 months of Stage 2. In PNG, only one data collection timepoint per clinic will be 276 completed. Data will also be collected on the costs of community engagement meetings, patient 277 education, clinical reviews, pharmacovigilance, staff training, serious adverse events (where relevant) 278 and malaria surveillance.

279

280 Social Science

281 During pre-implementation, purposive sampling of key stakeholders will be used to identify 282 participants for in-depth interviews to determine the acceptability and operational feasibility of 283 G6PD testing. Focus group discussions and in-depth interviews with malaria program officers at the 284 clinics, provincial and district health office representatives and health care providers will be held 285 during Stage 1 and Stage 2 to gather information on the practicality of the revised case management, challenges for implementation, and inefficiencies. Community-based health workers will also be 286 287 involved in focus group discussions. In PNG, a subset of community members that test positive with 288 P. vivax will be invited to be involved photovoice, to critically reflect on the clinical reviews and PQ. 289 adherence during day 3 and day 7 follow ups. Participant observations, informal conversations and 290 community engagement methods will be undertaken at the health clinics and certain sites in the 291 villages at several points during Stage 1 and Stage 2, across both PNG and Indonesia. The number of 292 participants involved in the social science research will vary by site, but the aim will be to reach a 293 broad spectrum of demographics, including participants of different ethnicity, sex and age (Table 6).

294

295 Table 6 Qualitative research activities

Activity	Participants	Time	Location	Duration	Audio recording
In-depth interviews	Clinic staff, patients (or their guardians), local health authorities, community leaders	Scheduled with participants during Stage 1 and 2	Participant's office/clinic/ house/research office (as appropriate and agreed upon with the participant)	45-90 minutes	Recorded if participant consented
Focus group discussions	Clinic staff, community- based health workers involved in community- based clinical review	Scheduled with participants during Stage 1 and 2	Clinic/ Research office/ community centre (as appropriate and agreed upon with the participants)	45-90 minutes	Recorded with participants' consent
Observations and informal interviews	Clinic staff, patients, community members	During community engagement activities in pre- implementation stage (community members) and at different time points throughout Stage 1 and Stage 2 (all participants)	Clinic, public places where community activities take place (e.g. community centres, religious congregations)	The whole duration of activity being observed	No audio recording
Photovoice (PNG Only)	Community members	Photovoice will be used to critically reflect on the clinical reviews and PQ adherence during day 3 and day 7 follow ups and will be undertaken with patients that test positive for P. vivax malaria and are prescribed PQ.	Community center (as appropriate and agreed upon with the participants)	4–6-week process of photo taking and co- analysis with communit y members	Audio recording of FGDs during co-analysis

297

298 Study objectives and related endpoints

- 299 The overall objective of the SCOPE study is to determine the safety, feasibility and cost-effectiveness
- 300 of high-dose primaquine after point of care G6PD testing. The study has additional subsidiary
- 301 objectives with associated endpoints, subdivided by study stage and objective category addressing
- 302 operational feasibility, cost-effectiveness, safety and pharmacovigilance (Table 7). The two primary
- 303 endpoints in Stage 1 include the proportion of patients experiencing at least one SAE during
- 304 treatment and the proportion of patients experiencing at least one AESI during treatment. In Stage 2
- 305 the primary endpoint is the proportion of patients with *P. vivax* malaria who correctly receive all
- 306 components of revised case management (including G6PD testing, treatment with PQ according to
- 307 the revised case management protocol and G6PD activity, patient education, supervision of the first
- 308 dose of PQ and community review on day 3).

309 Table 7 Study objectives and endpoints

Stage 1 Objectives and related endpoints (n=800)			
Primary Objective	Primary Endpoints		
To determine the safety of PQ in patients prescribed different treatment regimens	 Proportion of patients experiencing at least one SAE during treatment Proportion of patients experiencing at least one AESI during treatment 		
Secondary Objectives	Secondary Endpoints		
 Determine the risk of patients experiencing any AESI during treatment Determine the risk of patients experiencing 	 The proportion of patients with any AESI during treatment The proportion of patients with a gastrointestinal AESI during treatment 		
 severe GI events during treatment Determine the risk of patients experiencing severe haemolysis during treatment 	 AESI during treatment. The proportion of patients with an AESI related to haemolysis during treatment 		
 Determine the risk of patients experiencing severe methaemoglobinaemia Determine the tolerability of PQ in patients 	 The proportion of patients with an AESI related to methaemoglobinaemia Proportion of patients permanently stopping PQ 		
prescribed different treatment regimen	before end of treatment		
 Determine primaquine dosing accuracy by G6PD activity category 	 The proportion of patients receiving correct treatment based on G6PD activity 		
 Determine the proportion of patients receiving a clinical review on day 3 and day 7 of PQ 	 Proportion of patients who were reviewed on day 3 and day 7 		
treatment	Perception of and experience with new radical		
Qualitative assessment of potential bottlenecks	cure tools among health care providers and		

to the revised case management (G6PD testing, high dose 7-day primaquine, and day 3 & day 7)	community members.
to improve the implementation during Stage 2.	
Stage 2 Objectives and related endpoints (n=11,	•
Primary Objective	Primary Endpoint
To determine the operational feasibility of implementing revised case management for patients with <i>P. vivax</i> malaria	Proportion of patients with <i>P. vivax</i> malaria who correctly receive all components of revised case management (including G6PD testing, correct treatment of PQ according to revised case management and G6PD activity, patient education,
Operational Feasibility – Quantitative:	supervision of the first dose and community review of day 3)
	Sacandan, Endnainta
 Secondary Objectives Determine the proportion of health care practitioners who comply with the revised radical cure treatment algorithm Determine the proportion of patients with vivax malaria receiving a SD Biosensor G6PD test Determine primaquine dosing accuracy by G6PD activity category Determine the proportion of vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients) Determine the proportion of vivax malaria patients that are reviewed on day 3 Determine the proportion of vivax malaria patients that adhere to their prescribed primaquine regimen 	 Secondary Endpoints Proportion of health care practitioners who comply with the revised radical cure treatment algorithm Proportion of patients with vivax malaria receiving a SD Biosensor G6PD test Proportion of eligible vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test Proportion of vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients) Proportion of vivax malaria patients that are reviewed on day 3 Proportion of vivax malaria patients that adhere to their prescribed primaquine regimen
Operational Feasibility – Qualitative	
Secondary Objectives	Secondary Endpoints
 Understanding the acceptability and feasibility of the introduction and use of radical cure tools among health care providers. Reviewing the barriers and enablers of uptake and implementation at sub-national levels. Understanding the compliance with G6PD 	 Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified. Barriers and enablers of uptake and implementation at the sub-national levels are identified
 testing and perceptions of the drug regimens and serious adverse events among health care providers. Understanding the knowledge, skills and training required for health care providers to administer the revised case management and patient-counselling. 	 Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified Required knowledge, skills, and traininig to administer the revised case management and patient-counseling identified
• Understanding the barriers and facilitators to	• Factors influencing the barriers and facilitators to

 patient acceptance of G6PD testing and adherence to primaquine after the roll-out of the revised case management. Understanding the acceptability and feasibility of community-based clinical review at day 3 of primaquine treatment to detect and manage adverse effects. Understanding the perceptions of new radical cure tools and serious adverse events at the community level Determining the local acceptability of the revised case management algorithms among patients, their families and health care workers. 	 patient adherence to primaquine after the roll-out of the revised case management identified. Factors influencing the acceptability and feasibility of community-based clinical review at day 3 of primaquine treatment identified Perceptions of the new radical cure tools and serious adverse events at the community level identified. Local acceptability of the revised case management algorithms among patients, their families, and health care workers established.
Secondary Objectives	Secondary Endpoints
 Determine if the burden of <i>P. vivax</i> malaria and asymptomatic parasitaemia decreases after the introduction of the revised case management package from healthcare provider and societal perspectives Determine the overall cost-effectiveness of the revised case management 	 The monthly incidence of confirmed symptomatic <i>P. vivax</i> malaria episodes (mono infection or mixed) in the Pre-Implementation stage (minimum 3 months) versus Implementation Stage 2 (12 months) Prevalence of <i>P. vivax</i> parasitaemia in patients presenting with fever in the Pre-Implementation Survey during Stage 2 Cumulative risk of representation to the same clinic with symptomatic <i>P. vivax</i> malaria within 6 months in the Pre- and Post-Implementation Stage Cost per component of the revised case management package from a healthcare provider perspective, including health systems strengthening processes Cost per episode of <i>P. vivax</i> malaria in the Pre-Implementation Stages from the healthcare provider and societal perspectives in Indonesia. Cost per episode of <i>P. vivax</i> malaria from the healthcare provider and societal perspectives in PNG. Overall cost-effectiveness of changing policy if revised case management is effective as compared to usual care
Pharmacovigilance:	
Secondary Objectives	Secondary Endpoints
 Determine the proportion of community-based health workers who correctly act on early signs of haemolytic anaemia and GI events 	 Proportion of CbHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct

 Determine the number of patients identified through community surveillance system with serious adverse events 	 patient to discontinue treatment) Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management
Safety:	
Secondary objectives	Secondary endpoint
 Determine the safety of PQ under real-world conditions Determine the risk of patients experiencing at least one AESI during treatment Determine the risk of patients experiencing severe haemolysis during treatment Determine the risk of patients experiencing severe GI event during treatment Determine the risk of patients experiencing severe methaemoglobinaemia Determine the difference in severe anaemia prevalence between the pre- and post-implementation of the revised case management 	 The proportion of patients eligible to receive PQ who had a serious adverse event (SAE) during treatment The proportion of patients experiencing at least one AESI during treatment The proportion of patients with an AESI related to haemolysis during treatment The proportion of patients with a gastrointestinal AESI during treatment The proportion of patients with AESI related to methaemoglobinaemia Prevalence of severe anaemia in patients presenting with fever in the Pre-Implementation Survey

G6PD: Glucose-6-phosphate dehydrogenase; PQ: Primaquine; SAE: serious adverse event; AESI: adverse event of special
 interest; GI: gastrointestinal; CbHW: community-based health worker

312

313 Study participant selection and recruitment

314	Criteria for participation in the S	COPE study differ between	n the stages of the study (Table 2). To	o be
-----	-------------------------------------	---------------------------	---	------

315 included in the pre or post-implementation cross-sectional prevalence surveys, patients must have

316 presented to a study clinic with fever or history of fever within the last 48 hours and must consent to

317 the study procedures, including providing a finger-prick blood sample. For inclusion in Stage 1 or

Stage 2, patients must be >6 months of age and >5kg in weight (Indonesia) and >1 year of age in PNG

319 with microscopically or RDT-confirmed *P. vivax* mono- or mixed species infection. Patients will be

- 320 excluded from the Stage 1 and Stage 2 studies (but not routine malariometric surveillance data
- 321 collection) if they have a haemoglobin <8g/dL, are pregnant or breastfeeding an infant <6 months of
- 322 age in Indonesia or <12 months of age in PNG, have had a previous adverse reaction to primaquine,
- have evidence of severe malaria or need hospital admission or referral. Participants in the various
- 324 qualitative components of the study will be selected purposively to ensure adequate demographic

- distribution and representation from key stakeholders (Table 8). Patients with vivax malaria who
- 326 participate in the SCOPE study will receive a unique identification number along with a brief malaria-
- 327 related medical summary. Patients will be asked to bring their unique number with them for any
- 328 future appointments to enable linkage of repeated episodes.
- 329 Table 8. Participant recruitment and staff involved

Consent	Person recruiting	Consent Location	Method of recruitment
Stage 1 Stage 2	Research Staff Clinic Staff guided by Research Staff	Clinic	All patients with suspected malaria presenting at the clinic will be screened. Eligible patients will be given the option to participate. During the consent process, the additional activities required for the research component will be discussed.
Pre-implementation survey Post-implementation survey	Research Staff		200 patients with suspected malaria presenting at each clinic will be screened and if eligible they will be given the option to participate.
Qualitative and Health Economics			
 Economic surveys In-depth Interviews 	-	Clinic	Consecutive patients (or their guardians) will be asked to participate in a short survey at the end of their visit until the required sample of 30 patients at each stage at each clinic is reached. Purposive sampling will be used to recruit Clinic Staff involved in G6PD testing, prescription of high dose PQ, and patient education.
- Focus group discussions	Research Staff	Community	Purposive sampling will be used to recruit sub- national health authorities directly supervising malaria programs (e.g. Director of Public Health, Malaria Control Supervisors) and community leaders (e.g. village chiefs, religious leaders). Purposive sampling will be used to recruit community members with malaria (or parents of children with malaria) who attended study clinics. Participants will be identified during participant observations and subsequently contacted through community based health workers or Research Staff (or directly, if previous rapport has been established with the research team member) and asked to consent for interview. Community-based health workers involved in community members of similar age (>=18 years only), gender, and ethnicity will be approached through community-based health workers or
- Participant	-	Clinic	community leaders to ask for initial consent. Daily activities at the clinic will occur in the lab, outpatient desk and the pharmacy. These will be

observations			observed with permission from clinic manager. Informal conversations with Clinic Staff will be held during observation activities.
		Community	Research Staff will participate in public activities such as religious congregations, monthly child growth monitoring conducted by community health workers, home-based management of malaria programs etc. Informal conversations will be held with a spectrum of community members during observation activities.
- Photovoice (PNG Only)	Research staff	Community	Purposive sampling will be used to recruit community members with malaria who attended study clinics and participated in the initial interviews.

330

G6PD: Glucose-6-phosphate dehydrogenase; PQ: Primaquine.

331

332 Participant Consent

333 Individual written informed consent collected by trained researchers and clinic healthcare workers

will be obtained from participants (or their guardians in the case of minors) in the pre-and post-

implementation cross-sectional surveys, Stages 1 and 2, economic surveys, in-depth interviews, focus

336 group discussions and photovoice. In Indonesia, minors over the age of 11 years will be asked to sign

an assent form in addition to full written consent provided by their legal guardian. All patient

information and the consent documents will be provided in the relevant local language. Provisions

have been made for participants who are illiterate to have the consent documents read to them and

340 their written consent recorded via a "mark" witnessed by a third party independent of the study

team. Patients declining to participate in Stages 1 or 2 will receive malaria care as per national

342 guidelines. Participants will be told that they can withdraw consent at any time without risk of

343 prejudice, and only their data up to the time of withdrawal will be retained. Participants will remain

in the study for the duration of their treatment, and their completion of the study will be facilitated

345 by the community-based reviews. For qualitative observations of health workers, a waiver of consent

346 was granted by all ethics committees, and health centres will be made aware that observations on

347 staff will be carried out.

348

349 Patient and Public Involvement

350	Before the study commences, in-depth stakeholder engagement sessions will be held with clinic staff,
351	community leaders, religious and secular leaders, and the Ministries of Health. Engaged participants
352	will have the opportunity to provide feedback on the operating procedures and patient educational
353	materials and where possible, their feedback will be incorporated into the study. Community
354	awareness and engagement sessions in villages within the health facility catchment area will also be
355	conducted with the support of community leaders and clinic staff.

After the study is completed, there will be a process of community engagement with clinic staff, community leaders and community members to describe the results of the study and to gather feedback on possible refinement of future vivax malaria management and mechanisms for expansion into routine practice. Findings will be discussed with representatives from the respective National Malaria Control Programmes with respect to the viability of the intervention in terms of safety, feasibility, and cost-effectiveness.

362

363 Power and Sample Size

364 In Stage 1, 4 clinics will enrol 800 patients (500 in Indonesia and 300 in Papua New Guinea).

Assuming 764 of these patients will have a G6PD activity >70% and be eligible for PQ7 and

366 considering that the proportion of patients receiving short-course primaquine who have to stop

therapy within 7 days is 5%, this sample size will produce a 95% confidence interval for the true

368 proportion needing to stop treatment with a margin of error +/- 1.55%.

369

370 In Stage 2, the implementation study will be conducted at ten health facilities across Indonesia and

371 Papua New Guinea. Based on recruitment during Stage 1 and prior surveillance, we estimate a total

of 11,410 patients with vivax malaria will be eligible and recruited into Stage 2 in Indonesia and

Papua New Guinea. Across the 10 clinics participating in Stage 2, a mean of 136 patients with vivax

374	malaria are expected to be seen at each clinic per month, 60% of which (n=82) are predicted to be
375	relapses and therefore preventable with improved primaquine therapy. Assuming the
376	implementation package in Stage 2 will reduce the individual risk of relapse by 30%, the monthly
377	incidence of vivax malaria is expected to fall by 17 cases (12.6%) per month. With a two-sided alpha
378	of 0.05 and a predicted standard deviation of the mean variation in monthly numbers of vivax
379	malaria cases at each clinic of 15, our sample size would achieve 89% power to detect this difference
380	in incidence.
381	
382	The risk of recurrence will also be assessed at an individual level using comparisons with patients
383	recruited during the pre-implementation phase. Based on a presumptive sample size of 11,410
384	patients matched 1:1 with 11,410 patients with vivax malaria in the pre-implementation phase, our
385	sample size would have 100% power to detect a 30% reduction in individual risk of recurrence at 6
386	months and 92% power to detect a 10% reduction, assuming 10% loss to follow-up in each group
387	and a baseline risk of recurrence at 6 months of 20%.
388	If 70% of patients recruited into Stage 2 receive all components of the implementation package
389	correctly, a sample size of 11,410 will give a 95% confidence interval for the true proportion of +/-
390	0.84%. If 1% of patients are predicted to have a treatment-limiting haemolytic event, this sample
391	size will produce an estimate with a 95% confidence interval of +/-0.18%.
392	
393	Analysis

Quantitative analyses will be done according to an *a priori* statistical analysis plan (Supplementary
Data 5). Briefly, numbers (with denominators) and proportions receiving the components of the
intervention package and experiencing AESIs, or SAEs will be presented in graphical and tabular
format with associated 95% confidence intervals. The change in incidence of vivax malaria between
the pre-implementation Stage and Stage 2 will be shown graphically and the statistical significance
of observed changes will be assessed by fitting a segmented regression model accounting for

400	autocorrelation with adjustment for time-varying cofactors. For before versus after comparisons of
401	count data, such as number of vivax malaria cases per month, incidence rate ratios will be calculated
402	and negative binomial regression models fitted. Individual-level risk of representation with vivax
403	malaria will be calculated using survival techniques including Kaplan-Meier curves and Cox
404	proportional hazards regression.
405	
406	The costs to patients and their families of <i>P. vivax</i> infection and the total healthcare provider costs
407	(including costs of community engagement meetings, the patient education package, clinical
408	reviews, pharmacovigilance, staff training, severe adverse events (where relevant), and malaria
409	surveillance), will be used in combination with before-and-after case numbers to determine the
410	overall cost-effectiveness of the package of revised case management (cost per infection or
411	disability-adjust life-year averted). Pending discussions with decision makers, this may include a
412	budget impact analysis and/or a distributional cost-effectiveness analysis.
413	
414	Qualitative data will be set-up in a preliminary coding tree in NVivo based on operational
415	conceptualisation of relevant outcomes of the study, i.e., feasibility, acceptability and risk appraisal.
416	All written data will subsequently be entered and coded into the same NVivo project. Deductive
417	coding based on the preliminary coding tree and inductive coding to yield new findings will be done.
418	For Photovoice, analysis involves the collective interpretation of images by the community members
419	as a way of co-creating knowledge and co-constructing meaning. To facilitate the group discussions
420	of the photographs, the SHOWED guide is used with the following questions: What do we see here?
421	What is really happening here? How does this relate to our lives? Why does this concern, situation
422	or strength exist? How can we become empowered through our new understanding? What can we
423	do?

425 ETHICS AND DISSEMINATION

426 Ethics approval

- 427 This study protocol (Master Protocol Version 4.0, 28 April 2023) was approved by the World Health
- 428 Organization Ethics Committee (Indonesia: ERC 0003810, PNG ERC 0003892); Menzies School of
- 429 Health Research (HREC: 2023-4524), Alfred Health (Burnet Institute, Project No: 18/23), University of
- 430 Gadjah Mada (KE/FK/0079/EC/2023), University of Indonesia (KET
- 431 347/UN2.F1/ETIK/PPM.00.02/2023), University of Sumatra Utara (80/KEPK/USU/2023), Institute of
- 432 Tropical Medicine (1655/23), PNG Institute of Medical Research (PNGIMR) (IRB: 22.02), and the PNG
- 433 National Department of Health Medical Research Advisory Committee (MRAC: 22.66). The study was
- 434 registered on clinicaltrials.gov for Indonesia: NCT05879224 and PNG: NCT05874271. Changes to
- 435 protocols will be communicated to all involved ethics boards and relevant institutions and updated in
- the clinical trials registration. Stage 1 of the study began in October 2023 and was completed in
- 437 September 2024.

438

439 Participant Safety

440 Although pre-treatment G6PD testing will reduce the risk of severe drug-induced haemolysis, the risk 441 cannot be eliminated completely. Severe haemolysis may still occur from *P. vivax* parasitaemia alone, 442 misdiagnosis of G6PD status (due to an erroneous SD Biosensor result or human error by 443 misinterpretation or incorrect prescription of PQ) or another concomitant, undiagnosed 444 haemoglobin or red cell pathology such as the thalassaemia's. Staff will receive refresher training 445 sessions on the correct use of the SD Biosensor device and regular guality control will be undertaken 446 to reduce measurement error. The day 3 (and in the case of Stage 1, the day 7) clinical review has 447 been timed to maximise the likelihood of early detection of impending haemolysis or other severe 448 adverse effects of primaguine. Conservative and standardised clinical escalation pathways are 449 designed to adjust management strategies to mitigate the risk of adverse outcomes. (Figure 4).

- 450 Figure 4. Patient Review (Level 1, 2 and 3) and Adverse Event Collection Process.
- 451 Footnote: Study MD: Study medical doctor; PI: prinicipal investigator; GMM: global medical monitor; MMV CMO:
- 452 Medicines for Malaria Venture Chief Medical Officer.
- 453
- 454 Adverse Event Detection and Categorisation
- 455 The severity of adverse events will be graded according to the NCI Common Terminology Criteria for
- 456 Adverse Events (CTCAE vs 5.0) (33). In addition, the Hillmen urine colour chart will be used during
- 457 patient clinical reviews (34). Adverse Events of Special Interest (AESI) include haemolysis,
- 458 gastrointestinal events and methaemoglobinaemia. Criteria for a haemolytic AESI include one or
- 459 more of the following with onset after commencing PQ:
- 460 i. Grade 3 or 4: fatigue, breathlessness or dizziness
- 461 ii. Severe pallor or jaundice
- 462 iii. Dark urine (Hillmen score >7)
- 463 iv. Fall in haemoglobin from baseline >3g/dL
- 464 v. Fall in haemoglobin to <7g/dL
- 465 Gastrointestinal AESI criteria include Grade 3 or 4 abdominal pain, nausea, anorexia or vomiting, and
- 466 methaemoglobinaemia AESI criteria include: methaemoglobin >10%, with Grade 3 or 4
- 467 breathlessness or dizziness (Supplementary Data 4).
- 468 Serious Adverse Events (SAE) will be defined as an untoward medical occurrence irrespective of
- 469 cause that occurs after commencement of PQ that: results in death, is life threatening, requires
- 470 inpatient hospitalisation or prolongs existing hospitalisation, results in persistent or significant
- 471 disability/incapacity, is a congenital anomaly/birth defect or requires medical intervention to prevent
- 472 permanent impairment or damage.

474 Follow-up and Review of Adverse Events

Clinical referral pathways will be established for patients requiring advanced management of haemolysis or other adverse reactions. Community-based health care workers will actively engage communities during Stage 2 follow-up visits to identify individuals who died or required hospital admission, blood transfusion or dialysis after day 3. Prior to commencing the study, pharmacovigilance awareness will be raised in the community and at the emergency departments at local referral hospitals.

481 Immediately upon detection of an AESI or SAE, a cascade of adverse event reporting will be initiated

482 including submission of the Level 3 safety review and SAE form (if applicable) to the Study Doctor,

483 Global Medical Monitor (GMM), Principal Investigators, Study Sponsor and Chief Medical Officer

484 from Medicines for Malaria Venture. Where possible follow-up details of each event will be provided

485 to the GMM. Community-based health workers, research nurses and site medical practitioners will

486 take all appropriate steps to protect the safety of participants and will ensure follow-up of the

487 evolution of each adverse event until resolution or permanent stabilisation. The GMM will gather all

488 safety data and report to the Safety Review Team (SRT).

489 Data management

In Indonesia, hard copy clinic register, and case report forms will be stored in locked filing cabinets at
the clinics. Data from these forms will be transcribed into an electronic format using REDCap
(v14.6.11) data capture software. In PNG, all data will be collected directly into REDCap (v14.6.9)
software (35, 36). Automatic checks of data validity will be built into the data entry forms. Verbal
data from qualitative surveys will be recorded in MP3 or WAV format and subsequently transcribed
into written form using standard word processing software. Patient identifiers will be stripped from

496 datasets once data cleaning and preparation is complete. Deidentified research data will be stored

- 497 for the long-term in the original electronic format, in a unified large database that contains all
- 498 research data other than participant identifiable data.

499

500 Data monitoring

501 Study coordination

- 502 The study will be coordinated by two sponsors 1) Menzies School of Health Research, Darwin,
- 503 Australia (with study sites in Papua; Sumatera Utara; and Lampung, Indonesia, managed by YPKMP/
- 504 Universitas Gadjah Mada; Universitas Sumatra Utara; and University of Indonesia, respectively), and
- 505 2) Burnet Institute, Melbourne, Australia (with study sites in Baro, Mugil, Napapar and Wirui,
- 506 managed by the Papua New Guinea Institute of Medical Research). The sponsors will provide study
- 507 oversight via the principal investigators. Additionally, Medicines for Malaria Venture (MMV),
- 508 Geneva, will provide overall study oversight to the study sponsors. An insurance policy from each
- 509 Sponsor, will cover any potential medical costs if a patient becomes sick or injured because of the
- 510 study. The investigators and sponsors will have access to the final dataset.
- 511

512 Safety Review Team (SRT) and Safety Monitoring Committee (SMC)

513 The SRT and SMC will be established to monitor safety and conduct of the study. The SRT will be 514 managed by the GMM, and include members from the global study team, with an independent 515 chair. The SMC will only include independent experts, and take place during Stage 1 only. The SRT 516 will meet after every 100 patients to monitor and review individual participant safety data, or at 517 an ad-hoc basis in the case of any safety events during Stage 1 (Figure 4). At each meeting, the 518 SRT will vote on whether the study should be continued, modified or stopped. Interim analyses 519 will be performed after 400 patients and after completion of Stage 1 (800 patients). The SRT will 520 review the data package at these time points and forward a proposal to the SMC regarding the 521 appropriateness of study continuation. The SRT will approve the progress to Stage 2 based on the 522 SMC recommendations and endorsement from National Departments of Health in each country. 523 The SRT will meet quarterly during Stage 2.

524

525 Monitoring and Auditing

A study monitoring plan with detailed monitoring templates has been prepared separately for Indonesia and PNG. Each study site will have at least three monitoring visits throughout the study period. The frequency may be increased based on the monitor's recommendations at each site. Auditing will take place as per either the sponsor, MMV or the national health authority's request.

530 Dissemination

531 Dissemination plans include presentations at scientific conferences, peer-reviewed publications, and 532 reporting at the National Ministries of Health in both countries as well as provincial and district

533 health authorities in study locations.

534

535 **DISCUSSION**

536 Progress towards global elimination of *P. vivax* malaria has been slow, largely because of healthcare 537 providers' inability to prevent relapses safely and effectively. Recommended primaguine regimens 538 are prolonged and current doses are insufficient in many tropical areas. The risk of precipitating 539 drug-induced haemolysis in patients with G6PD deficiency limits the use of this critically important 540 drug in the many vivax-endemic areas where G6PD testing is unavailable. Short, high-dose 541 primaguine regimens have potential to improve patient adherence and thus treatment effectiveness 542 and rapid and reliable pre-treatment G6PD testing can facilitate individualised treatment for patients 543 and reduce the risk of adverse events. Shortened courses of primaquine at a total dose of 7mg/kg 544 are known to be efficacious for preventing relapse under trial conditions (23, 37) but the safety and 545 effectiveness in real-world use is unknown.

The SCOPE implementation study is designed to provide robust data on the feasibility, safety, costs, and cost-effectiveness of having the typical primaquine treatment duration for patients with vivax

548 malaria reduced to 7-days, by introducing pre-treatment point of care G6PD activity assessment and 549 then providing double the usual primaquine total dose (7mg/kg), basic community 550 pharmacovigilance and enhanced patient education. Following the Stage 1 phase, study conditions 551 will emulate real-world practice as closely as possible.

This study has several important strengths. It will enrol a large number of patients with vivax malaria and provide precise estimates of the frequency of key safety outcomes. Patients will be enrolled at 10 sites, encompassing widely disparate *P. vivax* endemicities ensuring generalisability of the results to many endemic areas. The intensive first phase with rigorous community-based pharmacovigilance ensures confidence in the safety of the interventions prior to large-scale roll-out in Stage 2 while longstanding malariometric surveillance data collection at the study clinics will improve the robustness of before-versus-after comparisons of vivax malaria incidence.

The study has several limitations. Non-study malaria control activities will continue throughout the study period and will confound analyses of temporal trends. Collection of informed consent for study participation will impact clinic workflow and create a deviation from a true, real-world patient experience. Patient migration, absence of a robust national identification system, and diverse treatment seeking behaviours may all result in incomplete detection of vivax malaria recurrence resulting in an attrition bias affecting analyses of individual risk of recurrence.

The SCOPE study is endorsed by the Indonesian and PNG Ministries of Health and aligns with national malaria control priorities. Evidence provided by this study is expected to guide national vivax malaria management strategies in both countries and aim to contribute to reducing the burden of vivax malaria.

569

570 LIST OF ABBREVIATIONS

571 ACT Artemisinin-based Combination Therapy

- 572 ADL Activity of Daily Living
- 573 AE Adverse Event
- 574 AESI Adverse Event of Special Interest
- 575 CbHW Community-based Health Worker
- 576 CQI Continuous Quality Improvement
- 577 FGD Focus Group Discussion
- 578 G6PD Glucose-6-Phosphate Dehydrogenase
- 579 G6PDd G6PD deficiency
- 580 GST Global Study Team
- 581 HCP Healthcare Provider
- 582 MoH Ministry of Health
- 583 NDA National Drug Authority
- 584 NDoH National Department of Health
- 585 NMCP National Malaria Control Program
- 586 PCR Polymerase Chain Reaction
- 587 PNG Papua New Guinea
- 588 PQ Primaquine
- 589 PQ7 Primaquine 1.0 mg/kg/day for 7 days
- 590 PQ14 Primaquine 0.5 mg/kg/day for 14 days
- 591 PQ8W Primaquine 0.75mg/kg/week for 8 weeks

- 592 RDT Rapid Diagnostic Test
- 593 SAE Serious Adverse Event
- 594 SCOPE Short COurse PrimaguinE for the radical cure of P. vivax
- 595 SMC Safety Monitoring Committee
- 596 SRT Safety Review Team
- 597 YPKMP Yayasan Pengembangan Kesehatan dan Masyarakat Papua (Papua Health and
- 598 Community Development Foundation)
- 599

600 **DECLARATIONS**

- 601 **Consent for publication:** All authors consent to publication
- 602 Availability of data and materials: The datasets that will be generated during the current study will
- 603 be made available from the corresponding authors on reasonable request.
- 604 Competing interests: The authors have no competing interests to declare
- 605 Funding: This study is funded by UNITAID. In Papua New Guinea this funding is funded through
- 606 PNGIMR, Burnet Institute in Melbourne, Victoria, Australia. In Indonesia this study is funded through
- 607 Yayasan Pengembangan Kesehatan dan Masyarakat Papua, and Menzies School of Health Research in
- 608 Darwin Australia.
- 609 **Patient and public involvement:** Patients and/or the public were involved consulted the design, or
- 610 conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for
- 611 further details.
- 612
- 613 Provenance and peer review: Not commissioned; externally peer reviewed

614 Acknowledgements:

- 615 We thank Emilie Alirol for assistance developing the design of the study and Piero Olliaro and
- 616 Arantxa Roca-Feltrer for reviewing advice on the study design and review of the protocol.

617

618 Author contributions


- 619 ML, JRP, AP, IS, RNP, LJR, ND, SD conceived the study and led the protocol development; ER, VSS, EN,
- 620 LF, MM, AR, RF, KM, PD , BL, PA, AD, GL, MT, AS, RN, SP, HH and EJ contributed to protocol
- development. ML, JRP, AP, IS, RNP, LJR, ND, SD, JA, LF, FA, SA, AS, RN, MM, MOK, VSS, ER, GL, KM, PD,
- 522 TD, HH, HD, TW contributed to study materials development. JAS, ND and RNP developed the
- 623 statistical analysis plan and GL the data management plan. All authors read and approved the final
- 624 protocol manuscript.

626 **References**

627 Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of the 1. 628 Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. 629 2. Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the Proportion of 630 Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. Am J 631 Trop Med Hyg. 2020;103(3):1094-9. 632 3. World Health Organisation. World Malaria Report 2023. 2023. 633 Rueangweerayut R, Bancone G, Harrell EJ, Beelen AP, Kongpatanakul S, Mohrle JJ, et al. 4. 634 Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate 635 Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers. Am J 636 Trop Med Hyg. 2017;97(3):702-11. 637 5. Thriemer K, Ley B, von Seidlein L. Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure. PLoS Med. 2021;18(4):e1003494. 638 639 TGA. Australian Public Assessment Report: Tafenoquine succinate 2019 [Available from: 6. 640 https://www.tga.gov.au/resources/auspar/auspar-tafenoguine-succinate-0. 641 7. FDA. Krintafel (Tafenoquine) 2018 [Available from: 642 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf. 643 8. FDA. Arakoda (Tafenoguine) Tablets 2018 [Available from: 644 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf. 645 9. Recht J, Ashley EA, White NJ. Use of primaguine and glucose-6-phosphate dehydrogenase 646 deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 647 2018;12(4):e0006230. 648 10. Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence 649 to primaguine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance 650 Network systematic review and individual patient data meta-analysis. Malar J. 2023;22(1):306. 651 Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, et al. Challenges for 11. 652 achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN 653 Vivax Working Group. Malar J. 2017;16(1):141. 654 World Health Organisation. WHO Guidelines for Malaria. Geneva: WHO; 2023. 12. 655 13. Devine A, Battle KE, Meagher N, Howes RE, Dini S, Gething PW, et al. Global economic costs 656 due to vivax malaria and the potential impact of its radical cure: A modelling study. PLoS Med. 657 2021;18(6):e1003614. 658 14. Paediatric Society of Papua New Guinea. Standard Treatment for Common Illnesses of 659 Children in Papua New Guinea. 2016. 660 15. Ministry of Health Republic of Indonesia. Pocket book on Malaria Case Management. 2023. 661 Rahmalia A, Poespoprodjo JR, Landuwulang CUR, Ronse M, Kenangalem E, Burdam FH, et al. 16. 662 Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-663 methods study. Malar J. 2023;22(1):162. 664 Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. 17. 665 Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern 666 Papua: A hospital-based cohort study. PLoS Med. 2017;14(8):e1002379. 667 18. Poespoprodjo JR, Burdam FH, Candrawati F, Ley B, Meagher N, Kenangalem E, et al. 668 Supervised versus unsupervised primaguine radical cure for the treatment of falciparum and vivax 669 malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet 670 Infect Dis. 2021. 671 Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of 19. 672 artemether-lumefantrine and chloroguine with and without primaguine for the treatment of 673 Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med. 674 2017;14(5):e1002299.

675 20. Baird JK, Hoffman SL. Primaguine Therapy for Malaria. Clinical Infectious Diseases. 676 2004;39(9):1336-45. 677 21. Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, et al. Effect of primaguine 678 dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review 679 and individual patient data meta-analysis. Lancet Infect Dis. 2023. 680 22. Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al. Chloroquine Versus 681 Dihydroartemisinin-Piperaguine With Standard High-dose Primaguine Given Either for 7 Days or 14 682 Days in Plasmodium vivax Malaria. Clin Infect Dis. 2019;68(8):1311-9. 683 23. Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. 684 Short-course primaguine for the radical cure of Plasmodium vivax malaria: a multicentre, 685 randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394(10202):929-38. 686 Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. 24. 687 Haematologica. 2006;91(10):1303-6. 688 25. Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaguine dose and the 689 risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and 690 individual patient data meta-analysis. Lancet Infect Dis. 2023. 691 26. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD 692 Heterozygous Females Treated with Primaguine for Plasmodium vivax Malaria: A Nested Cohort in a 693 Trial of Radical Curative Regimens. PLoS Med. 2017;14(2):e1002224. 694 27. Yilma D, Groves ES, Brito-Sousa JD, Monteiro WM, Chu C, Thriemer K, et al. Severe Hemolysis 695 during Primaguine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual 696 Patient Data Descriptive Analyses. Am J Trop Med Hyg. 2023;109(4):761-9. 697 28. Ley B, Winasti Satyagraha A, Rahmat H, von Fricken ME, Douglas NM, Pfeffer DA, et al. 698 Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-699 phosphate dehydrogenase deficiency: A systematic review and meta-analysis. PLoS Med. 700 2019;16(12):e1002992. 701 Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a Novel 29. 702 Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing 703 for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient. Am J Trop Med Hyg. 704 2019;100(1):213-21. 705 30. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of 706 quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS 707 One. 2018;13(11):e0206331. 708 31. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 709 statement: extension to randomised pilot and feasibility trials. Pilot and Feasibility Studies. 710 2016;2(1). 711 SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal 32. 712 Medicine. 2013;158(3):200-7. 713 33. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) 2020 [Available from: 714 https://ctep.cancer.gov/protocoldevelopment/electronic applications/ctc.htm. 715 34. Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of Eculizumab 716 on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. 717 New England Journal of Medicine. 2004;350(6):552-9. 718 35. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data 719 capture (REDCap)--a metadata-driven methodology and workflow process for providing translational 720 research informatics support. J Biomed Inform. 2009;42(2):377-81. 721 36. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: 722 Building an international community of software platform partners. J Biomed Inform. 723 2019;95:103208. 724 37. Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaquine radical 725 cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and

- 726 Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. The
- 727 Lancet. 2023.





	Pre- implementation Stage	Stage 1				Stage 2			
	Day 0	Day 0	Day 3	Day 7	Unplanned Visit	Day 0	Day 3	Unplanned Visit	
Location	Clinic	Clinic	Community or clinic by a nurse	Community or clinic by a nurse	Clinic	Clinic	Community by a CHW ^L	Clinic	
Routine review and diagnosis	x	х				х			
Consent	x	х				X2			
Capillary blood sample									
Hb	X	х	X	x	+/- X	х		+/- X	
G6PD	x	х				х			
Microscopy	X				+/- X	X1		+/- X	
Treatment/Prescription	If applicable	х				х			
Education		х				х			
Supervision of first dose		Х				Х			
Drug supply	If applicable	х				х			
Adverse event data collection		х	×	x	x	х	х	x	
Community pharmacovigilance ⁴		х	х	x	x	х	x	x	

